title: Influence of CXCR4/SDF-1 axis on E-cadherin/β-catenin complex expression in HT29 colon cancer cells.
abstract: OBJECTIVE
  To study the influence of CXCR4/stromal cell-derived factor-1 (SDF-1) axis on E-cadherin/β-catenin complex expression in HT29 colon cancer cells and its underlying mechanisms.
  
  
  METHODS
  Effect of SDF-1 on E-cadherin/β-catenin expression was detected by immunocytochemistry. E-cadherin and β-catenin mRNA expression levels were measured by reverse transcriptase-polymerase chain reaction. SDF-1-induced phosphorylation of phosphatidylinositol 3-kinase (PI3K)/AKT and β-catenin was detected by Western blotting.
  
  
  RESULTS
  The E-cadherin and β-catenin mRNA expression levels in HT29 cells were lower 48 h after incubated with SDF-1 at the concentrations of 20 and 40 ng/mL (P<0.05). SDF-1-induced significant phosphorylation of PI3K/AKT and β-catenin. AMD3100 and LY294002 inhibited the phosphorylation of PI3K/AKT and β-catenin.
  
  
  CONCLUSIONS
  SDF-1 down-regulates the E-cadherin/β-catenin complex expression in HT29 cells by decreasing mRNA synthesis and increasing β-catenin phosphorylation.
authors.affiliation: Department of General Surgery, Qilu Hospital, Shandong University, Jinan 250012, Shandong Province, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.forename: Cui-Ling
authors.initials: CL
authors.lastname: Li
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Wen-Bin
authors.initials: WB
authors.lastname: Yu
authors.forename: Hai-Peng
authors.initials: HP
authors.lastname: Yin
authors.forename: Guang-Yong
authors.initials: GY
authors.lastname: Zhang
authors.forename: Li-Feng
authors.initials: LF
authors.lastname: Zhang
authors.forename: Sheng
authors.initials: S
authors.lastname: Li
authors.forename: San-Yuan
authors.initials: SY
authors.lastname: Hu
mesh_terms: D015820:Cadherins / Q000235:genetics / Q000378:metabolism*; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation / Q000187:drug effects; D054377:Chemokine CXCL12 / Q000378:metabolism / Q000494:pharmacology*; D003110:Colonic Neoplasms / Q000235:genetics / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000378:metabolism; D019073:HT29 Cells / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D058539:Phosphatidylinositol 3-Kinase / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000235:genetics / Q000378:metabolism*; D051176:beta Catenin / Q000235:genetics / Q000378:metabolism*
chemical_list: C527276:CXCR4 protein, human; D015820:Cadherins; D054377:Chemokine CXCL12; D004791:Enzyme Inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors; D012333:RNA, Messenger; D019718:Receptors, CXCR4; D051176:beta Catenin; D058539:Phosphatidylinositol 3-Kinase; D051057:Proto-Oncogene Proteins c-akt